Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Authors: Siddharth Jain, Arghya Chattopadhyay, Aman Sharma
Journal: Annals of Internal Medicine (2020)

Letters1 December 2020Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated VasculitisSiddharth Jain, MD, Arghya Chattopadhyay, MD, and Aman Sharma, MDSiddharth Jain, MDPostgraduate Institute of Medical Education and Research, Chandigarh, India (S.J., A.C., A.S.)Search for more papers by this author, Arghya Chattopadhyay, MDPostgraduate Institute of Medical Education and Research, Chandigarh, India (S.J., A.C., A.S.)Search for more papers by this author, and Aman Sharma, MDPostgraduate Institute of Medical Education and Research, Chandigarh, India (S.J., A.C., A.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1197 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read the article by Charles and colleagues (1) with great interest. It is well known that the duration of maintenance therapy in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is uncertain (2). A need for prolongation was first highlighted by the long-term follow-up results of the MAINRITSAN (Maintenance of Remission Using Rituximab in Systemic ANCA-Associated Vasculitis) trial (3). The authors should be complimented for having now addressed this research question in the ingenious trial design of MAINRITSAN3 (1). However, certain aspects of this trial merit consideration.First, at the time of assessment for eligibility, 15 (9.5%) of ...References1. Charles P, Perrodeau É, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis. A randomized trial. Ann Intern Med. 2020;173:179-87 LinkGoogle Scholar2. Mishra DP, K Naidu GS, Sharma A. Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitis. Indian J Rheumatol. 2019;14:218-28. CrossrefGoogle Scholar3. Terrier B, Pagnoux C, Perrodeau É, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77:1150-6. [PMID: 29724729] CrossrefMedlineGoogle Scholar4. Charles P, Terrier B, Perrodeau É, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-9. [PMID: 29695500] CrossrefMedlineGoogle Scholar5. Second Edition Update Working Group. Clinical Guidelines for Immunoglobulin Use. 2nd ed. Department of Health; 2011. Google Scholar Author, Article, and Disclosure InformationAffiliations: Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.J., A.C., A.S.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1197. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLong-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Pierre Charles , Élodie Perrodeau , Maxime Samson , Bernard Bonnotte , Antoine Néel , Christian Agard , Antoine Huart , Alexandre Karras , François Lifermann , Pascal Godmer , Pascal Cohen , Catherine Hanrotel-Saliou , Nicolas Martin-Silva , Grégory Pugnet , François Maurier , Jean Sibilia , Pierre-Louis Carron , Pierre Gobert , Nadine Meaux-Ruault , Thomas Le Gallou , Stéphane Vinzio , Jean-François Viallard , Eric Hachulla , Christine Vinter , Xavier Puéchal , Benjamin Terrier , Philippe Ravaud , Luc Mouthon , Loïc Guillevin , and Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Thomas D. Garvey , Kenneth J. Warrington , and Matthew J. Koster Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Pierre Charles and Loïc Guillevin Metrics 1 December 2020Volume 173, Issue 11Page: 947KeywordsBiologicsConflicts of interestDisclosureDisease modifying antirheumatic drugsDrugsForecastingIntravenous immunoglobulinRheumatoid arthritisSafetyVasculitis ePublished: 1 December 2020 Issue Published: 1 December 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...